Bonita David P, a director at Windward Bio Group AG (NASDAQ: WWB), bought $20.00 million of company stock on November 16th, 2026. The purchase covered 1,176,471 shares.
Every share in the transaction was priced at $17.00. There is no spread to parse here: the reported price range runs from $17.00 to $17.00, which is the signature of a single block rather than a series of open market fills gathered across a session.
Windward Bio Group AG operates in biological products (no diagnostic substances), a corner of the market where cash position and dilution tend to drive the share count as much as operating results do. A director writing a check of this size is therefore worth reading against the company's own capital needs rather than against a trading thesis.
On size, the purchase is large relative to the company. Windward Bio Group AG carries a market capitalization of $1,393,510,400, so $20.00 million of stock bought by one individual director is a meaningful slice of the float to move in a single day, and it is an unusually large personal commitment by the standards of director-level buying.
The other side of the ledger is thin, and that is part of the story. The record shows one filing and one buyer. There is no accompanying cluster of purchases from other officers or directors to corroborate it, and no offsetting sale activity in the window either. Readers who want confirmation from a second insider will not find it in this disclosure.
Price context matters most. The director paid $17.00 per share. WWB last traded at $24.01, above the level at which the block was struck. Anyone reading this after the fact is looking at a higher entry point than the filer had, and the gap between the two numbers is the first thing to weigh.
Figures above come from the Form 4 filed with the Securities and Exchange Commission and from our own reconciled transaction tables.
Track every Form 4 filed at WINDWARD BIO GROUP AG (WWB) → insiderbuying.com/companies/WWB

